New strategic partnership to advance affordable cell and gene therapies for underserved

Caring Cross, a US-based non-profit dedicated to expanding global access to advanced therapies, has announced a new partnership with the Amrita Research Center Delhi (ARCD) and Amrita Vishwa Vidyapeetham, a leading multi-campus, research-intensive university in India.

Together, the organisations will develop and implement affordable, scalable cell and gene therapy (CGT) solutions to treat diseases affecting underserved communities, particularly Sickle Cell Disease, Thalassemia, and various cancers.

Cell and gene therapies have emerged as transformative medical innovations capable of curing or significantly improving the outcomes of previously incurable diseases. However, their exceptionally high cost has limited their accessibility around the world. This partnership aims to change that reality in India — a country with a population of 1.4 billion and a substantial burden of hereditary blood disorders and cancers that disproportionately affect lower-income and historically underserved communities.

Through this collaboration, ARCD and Caring Cross will establish decentralised therapeutic advanced manufacturing designed to reduce the cost of delivering cures at the point of care. This includes advancing TriCAR-T cell therapies for the treatment of Leukemia and Lymphoma, and other next-generation affordable CGT platforms focused on equitable access.